DNA Methylation Inhibitors in the Treatment of Leukemias, Myelodysplastic Syndromes and Hemoglobinopathies: Clinical Results and Possible Mechanisms of Action
- 1 January 2000
- book chapter
- Published by Springer Nature
- Vol. 249, 135-164
- https://doi.org/10.1007/978-3-642-59696-4_9
Abstract
No abstract availableThis publication has 52 references indexed in Scilit:
- Activation of the retinoic acid receptor ?? gene by 5-aza-2???-deoxycytidine in human DLD-1 colon carcinoma cellsAnti-Cancer Drugs, 1997
- Treatment with Azacitidine of Patients with End-Stage β-ThalassemiaNew England Journal of Medicine, 1993
- The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup studyAnnals of Hematology, 1992
- 5-aza-2′-deoxycytidine in advanced or recurrent cancer of the uterine cervixEuropean Journal of Cancer and Clinical Oncology, 1991
- Phase II study of 5-Aza-2′-deoxycytidine in advanced ovarian carcinomaEuropean Journal of Cancer and Clinical Oncology, 1990
- The EORTC early clinical trials cooperative group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomasEuropean Journal of Cancer and Clinical Oncology, 1987
- MODULATION OF HLA-DR ANTIGENS EXPRESSION IN HUMAN MYELOID LEUKAEMIA CELLS BY CYTARABINE AND 5-AZA-2'-DEOXYCYTIDINEThe Lancet, 1984
- 5-Azacytidine Selectively Increases γ-Globin Synthesis in a Patient with β+ThalassemiaNew England Journal of Medicine, 1982
- Response to 5-azacytidine in patients with refractory acute nonlymphocytic leukemia and association with chromosome findingsCancer, 1982
- DNA methylation in the human γδβ-globin locus in erythroid and nonerythroid tissuesCell, 1980